声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 点击查看公告原文>> 责任编辑：小浪快报 8月22日，特一药业集团股份有限公司通过电话会议的形式，接受了国盛证券、华鑫证券等12家机构的 特定对象调研。公司董事长、总经理许荣煌等相关人员参与接待。 投资者关系活动重要信息投资者活动关系类别：特定对象调研、电话会议时间：2025年8月22日地点： 电话会议参与单位名称：国盛证券、华鑫证券、山西证券、光大证券、申万宏源证券、浙商证券、东方 财富证券、西南证券、天风证券、华安证券、华创证券、东吴证券上市公司接待人员姓名：董事长、总 经理许荣煌；董事、财务总监、副总经理陈习良；董事会秘书许紫兰；证券事务代表徐少华 投资者关系活动主要内容公司经营情况显著改善： ...

证券代码：002728 证券简称：特一药业 特一药业集团股份有限公司投资者关系活动记录表 编号：2025-006 | | 特定对象调研 分析师会议 | | | --- | --- | --- | | 投资者关系活 | 媒体采访 业绩说明会 | | | 动类别 | 新闻发布会 路演活动 | | | | 现场参观 | | | | 其他 电话会议 | | | 活动参与人员 | 国盛证券：张金洋、张玉 | | | | 华鑫证券：胡博新 | | | | 山西证券：邓周宇、杜鹏程 | | | | 光大证券：王明瑞、黄素青 | | | | 申万宏源证券：张静含、凌静怡 | | | | 浙商证券：王班、吴天昊、丁健行 | | | | 东方财富证券：何玮、崔晓倩 | | | | 西南证券：杜向阳、王钰玮 | | | | 天风证券：杨松、李臻 | | | | 华安证券：谭国超、熊骥溟 | | | | 华创证券：郑辰、高初蕾、赵建韬 | | | | 东吴证券：朱国广、李倩 | | | 上市公司接待 | 董事长、总经理：许荣煌 董事、财务总监、副总经理：陈习良 | | | 人员 | 董事会秘书：许紫兰 | | | | ...

Sales Goals and Market Potential - The company aims to sell 100 million boxes of cough tablets within 3-5 years, with a focus on achieving this target post-reform [1] - The cough tablets have a significant market potential due to low coverage in certain areas, which will be addressed after the marketing organization transformation [2] - The aging population (31 million people aged 60 and above, accounting for 22% of the population) increases the consumer base for cough and phlegm products [2] Product Efficacy and Production Capacity - The cough tablets have a clinical effectiveness rate of 93%, with a significant effect on chronic coughs [1] - Current production capacity is 1.8 billion tablets, with potential to increase to 2.4 billion based on market demand [2] - Sales data shows a recovery trend, with 230 million tablets sold in 2024 and 217 million in Q1 2025 [2] Marketing and Organizational Changes - The company is undergoing a marketing transformation, shifting from a distributor model to a self-operated and promotional service model [3] - New departments have been established to enhance marketing efforts, including self-operated sales, online marketing, and brand market departments [3] - The company is expanding its online sales channels, with significant growth in B2C and O2O platforms [4][11] Brand Development and Consumer Engagement - The company is enhancing brand recognition through a mix of traditional and new media advertising [4][12] - The marketing strategy includes collaboration with major pharmacy chains and community pharmacies to increase consumer education and engagement [5][12] - The company aims to strengthen its brand through targeted advertising and promotional activities across various platforms [5][12] Financial Performance and Product Diversification - In 2023, cough tablets accounted for 41.96% of the company's revenue, indicating a strong reliance on this product [8] - Other products collectively contribute over 50% of revenue, mitigating dependency risks [8] - The company is focusing on promoting other products like skin disease and blood toxin pills to diversify its portfolio [9][10]

Core Viewpoint - The company is undergoing significant marketing organizational changes and adjustments to its sales channels, which have impacted its 2024 financial performance, leading to a substantial decline in net profit and revenue [10][12]. Group 1: Financial Performance - In 2024, the company achieved an operating income of 687.79 million yuan, a year-on-year decrease of 35.55% [10]. - The net profit attributable to shareholders was 20.50 million yuan, down 91.90% year-on-year [10]. - The company has reduced shipments of its core product, Zhi Ke Bao Pian, which has led to a significant drop in sales revenue for this high-margin product [10]. Group 2: Marketing and Sales Strategy - The company is transitioning from a distributor model to a mixed model of self-operated and promotional service providers in its pharmacy sales [10]. - Marketing expenses have increased significantly as the company aims to enhance brand awareness and reputation, resulting in a higher proportion of sales expenses [10]. - The company plans to leverage digital marketing and expand its marketing channels, including social media platforms like Douyin and Xiaohongshu, to improve product visibility [3][10]. Group 3: Product Focus and Development - The company considers Zhi Ke Bao Pian as its core product, with plans to increase its sales to 100 million boxes within 3-5 years post-reform [3]. - The company is also focusing on developing a product cluster around Zhi Ke Bao Pian, which includes other traditional Chinese medicine products [3]. - The company has a production capacity of 1.8 billion pieces for Zhi Ke Bao Pian, with potential to expand to 2.4 billion pieces [3]. Group 4: Governance and Future Plans - The company is committed to improving its corporate governance and is open to external growth opportunities, including mergers and acquisitions, to enhance its competitive edge [5][14]. - The management emphasizes the importance of internal growth while also considering external partnerships to strengthen the company's market position [5][14]. - The company aims to maintain a strong focus on traditional Chinese medicine products, aligning with national policies that support the industry [6][14].

Group 1: Product Performance and Market Potential - The core product, Zhi Ke Bao, shows significant efficacy for chronic cough, with a clinical control efficiency of 73% and a total effective rate of 93% [2] - The product has a large consumer base, with 310 million people aged 60 and above in China, representing 22% of the population, indicating a growing market for cough remedies [2] - Zhi Ke Bao has sufficient production capacity, currently at 1.8 billion pieces, with potential to increase to 2.4 billion pieces based on market demand [2] Group 2: Financial Performance and Challenges - In 2024, the company reported a revenue of 68,778.52 million yuan, a decrease of 35.55% year-on-year, and a net profit of 2,049.50 million yuan, down 91.90% [6] - The decline in revenue was attributed to a reduction in shipments of Zhi Ke Bao during a marketing organizational transformation, which also led to increased sales expenses [6][10] Group 3: Marketing and Sales Strategy - The company is transitioning from a distributor model to a mixed model of self-operated and promotional service providers to enhance sales efficiency [6] - Marketing efforts are being diversified, with a focus on digital marketing and increased brand awareness through various media channels, including social media platforms [27][30] Group 4: Research and Development Focus - The company is committed to developing traditional Chinese medicine products, with ongoing projects in skin disease treatments and diabetes management [3][5] - There is an emphasis on integrating raw material and formulation development to enhance the quality and competitiveness of chemical drugs [8] Group 5: Future Growth Strategies - The company plans to strengthen its marketing organization and expand its product offerings, particularly in the traditional Chinese medicine sector [7][30] - There is a potential for mergers and acquisitions to enhance growth and market presence, contingent on finding suitable targets [31][32]